Kenneth Krogulski - 02 Oct 2023 Form 4 Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Director
Signature
Kenneth J. Krogulski by /s/ John Hamm as attorney-in-fact
Issuer symbol
CPIX
Transactions as of
02 Oct 2023
Transactions value $
$5,962
Form type
4
Filing time
17 Oct 2023, 17:04:21 UTC
Previous filing
03 Oct 2023
Next filing
03 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $529 +280 +0.13% $1.89 219,446 02 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $518 +280 +0.13% $1.85 219,726 03 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $406 +227 +0.1% $1.79 219,953 04 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $518 +280 +0.13% $1.85 220,233 05 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $526 +280 +0.13% $1.88 220,513 06 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $577 +280 +0.13% $2.06 220,793 09 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $571 +280 +0.13% $2.04 221,073 10 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $571 +280 +0.13% $2.04 221,353 11 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $596 +280 +0.13% $2.13 221,633 12 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $580 +280 +0.13% $2.07 221,913 13 Oct 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $568 +280 +0.13% $2.03 222,193 16 Oct 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023.